Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
More Americans are using GLP-1 medications to lose weight than ever before. The numbers tell a striking story.
New survey data shows that about 11% of US adults used a GLP-1 drug for weight management in 2026. Back in 2024, that number stood at just 3%. In other words, usage more than tripled in two years. Overall, 15% of adults say they’ve tried one of these drugs for weight loss at some point.
The science behind these medications has a surprisingly odd origin story. Semaglutide, the compound in Ozempic and Wegovy, actually traces back to research on Gila monster saliva in 2008. Scientists spotted a peptide in the venom that closely resembled a human hormone called GLP-1. This hormone helps regulate insulin and blood sugar in people with type 2 diabetes. That discovery eventually led Novo Nordisk to launch Ozempic in 2017 as a diabetes treatment.
It didn’t take long for doctors and patients to notice something else. People were losing significant weight on the drug. So Novo Nordisk built on that effect and developed Wegovy specifically for weight management. The FDA approved it for chronic weight loss in 2021, and demand has climbed steadily ever since.
Both drugs require a prescription, and for good reason. Doctors usually start patients on a low dose and increase it gradually. This approach helps patients avoid nausea and other stomach-related side effects. Because of this, medically supervised treatment matters throughout the process.
Cost remains one of the biggest barriers to access. Patients with insurance that covers GLP-1 drugs for diabetes might pay between $25 and $100 a month. Coverage specifically for obesity treatment, when available, tends to cost more, typically $100 to $300 monthly.
Without insurance, the price climbs fast. Brand-name GLP-1 drugs can run $900 to $1,400 a month out of pocket. Over a year, that adds up to as much as $12,000. As a result, cost pressure has pushed many patients toward alternatives.
This price gap helps explain a growing trend toward compounded versions of these drugs. Brand-name medications still make up 68% of the market. However, compounded or custom-mixed alternatives now account for 19%. In fact, roughly a third of current GLP-1 users have switched from brand-name to compounded versions at some point, mostly to save money.
The FDA isn’t thrilled about this shift. The agency has issued compounding risk alerts about these products, citing concerns over dosing accuracy and inconsistent quality control. Unlike brand-name drugs, compounded versions skip the same rigorous approval process. Consequently, there’s less oversight guaranteeing what’s actually in each dose. Health officials continue to urge patients to talk to their doctors before switching.
Meanwhile, a bigger public health story is unfolding alongside all this. The US obesity rate dropped to 36.4% in 2026, down from a record high of 39.9% in 2022. It’s tempting to credit GLP-1 drugs for that shift. However, researchers caution that diet, exercise, and other medical interventions likely play a role too.
Still, these medications are reshaping how Americans approach weight loss treatment. The debate over cost, access, and safety isn’t going away soon. As demand grows, insurers, regulators, and drugmakers will face more pressure to make these treatments both safe and affordable.
